Scientific Presentations

Tolerability and Preliminary Efficacy of BXQ-350 for Solid Tumors and Gliomas: First-in-human, first-in-class phase 1 trial

Conflict of Interest Statement: Dr. Rixe holds a minor (<0.01%) equity interest in Bexion Pharmaceuticals, Inc.

On Tuesday, June 22, 2021, Dr. Ray Takigiku, Founder and CEO of Bexion, participated in AngelMD’s Pitch Club, “Innovations in Oncology”.